226 related articles for article (PubMed ID: 35791797)
1. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of
Choi YJ; Lee YC; Kim JM; Kim JI; Moon JS; Lim YJ; Baik GH; Son BK; Lee HL; Kim KO; Kim N; Ko KH; Jung HK; Shim KN; Chun HJ; Kim BW; Lee H; Kim JH; Chung H; Kim SG; Jang JY
Gut Liver; 2022 Jul; 16(4):535-546. PubMed ID: 35791797
[TBL] [Abstract][Full Text] [Related]
2. Treatment of
Kanu JE; Soldera J
World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
[TBL] [Abstract][Full Text] [Related]
3. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.
Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Park CH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1911-1918. PubMed ID: 35816283
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Sohn CI; Park CH
Gut Liver; 2023 Sep; 17(5):711-721. PubMed ID: 36510776
[TBL] [Abstract][Full Text] [Related]
5. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line
Kim JY; Lee SY; Kim H; Kim JH; Sung IK; Park HS
Yonsei Med J; 2021 Aug; 62(8):708-716. PubMed ID: 34296548
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
Kim JS; Ko W; Chung JW; Kim TH
Helicobacter; 2023 Jun; 28(3):e12977. PubMed ID: 37083222
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Asaka M; Sugiyama T; Kato M; Satoh K; Kuwayama H; Fukuda Y; Fujioka T; Takemoto T; Kimura K; Shimoyama T; Shimizu K; Kobayashi S
Helicobacter; 2001 Sep; 6(3):254-61. PubMed ID: 11683930
[TBL] [Abstract][Full Text] [Related]
10. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant
Lee JW; Kim N; Nam RH; Yu JE; Son JH; Lee SM; Lee DH
Gut Liver; 2021 Jan; 15(1):53-60. PubMed ID: 33191308
[TBL] [Abstract][Full Text] [Related]
13. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for
Kim BJ; Lee H; Lee YC; Jeon SW; Kim GH; Kim HS; Sung JK; Lee DH; Kim HU; Park MI; Choi IJ; Yoon SM; Kim SW; Baik GH; Lee JY; Kim JI; Kim SG; Kim J; Lee J; Kim JG; Kim JJ;
Gut Liver; 2019 Sep; 13(5):531-540. PubMed ID: 31505907
[TBL] [Abstract][Full Text] [Related]
14. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
15. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
[TBL] [Abstract][Full Text] [Related]
16. Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
Uygun A; Kadayifçi A; Yeşilova Z; Savaş MC; Ateş Y; Karslioğlu Y; Ciğerim M; Bağci S; Dağalp K
Turk J Gastroenterol; 2004 Dec; 15(4):219-24. PubMed ID: 16249974
[TBL] [Abstract][Full Text] [Related]
17. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
[TBL] [Abstract][Full Text] [Related]
19. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
[TBL] [Abstract][Full Text] [Related]
20. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
Prasertpetmanee S; Mahachai V; Vilaichone RK
Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
